Form 4: Precipio CFO Matthew Gage Receives Stock Options

Precipio's Chief Financial Officer, Matthew Gage, was granted 5,000 stock options with an exercise price of $23.82, vesting upon the company's common stock reaching a $40 VWAP.

Summary

• Matthew Gage, Chief Financial Officer of Precipio, Inc. (PRPO), acquired 5,000 stock options.
• The transaction date for the option grant was January 2, 2026.
• Each option has an exercise price of $23.82 per share.
• The options will vest and become exercisable only when the 10-day volume-weighted average price (VWAP) of Precipio's common stock exceeds $40 per share.
• The options expire on January 2, 2036.
• The options were issued pursuant to Precipio's Equity Incentive Plan as compensation for Mr. Gage's service as an officer.
• Following this transaction, Mr. Gage beneficially owns 5,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The filing indicates a standard executive compensation grant designed to align management incentives with shareholder value, which is generally positive, but it does not contain new operational or financial performance data.

Positives

• The grant of stock options aligns the Chief Financial Officer's financial interests with those of shareholders, as the options only vest upon significant appreciation of the company's stock price (10-day VWAP exceeding $40 per share).
• The issuance under an Equity Incentive Plan is a standard practice for executive compensation, promoting long-term commitment and performance.

Negatives

• The vesting condition tied to a $40 VWAP represents a substantial hurdle, indicating that the options may not vest if the company's stock price does not achieve significant growth.

Risks

• The primary risk is that the company's common stock may not achieve a 10-day volume-weighted average price exceeding $40 per share, in which case the granted options would not vest and become exercisable.

Future Outlook

The vesting condition for the stock options implies a future target for Precipio's common stock to exceed a $40 10-day volume-weighted average price, indicating management's incentive to drive significant share price appreciation over the next decade.

Industry Context

The grant of performance-based stock options is a common executive compensation strategy across various industries, particularly in growth-oriented sectors like biotechnology and diagnostics, to incentivize leadership to achieve specific financial or operational milestones that enhance shareholder value.

Comparison to Industry Standards

• The grant of performance-based stock options to a Chief Financial Officer is a common practice in the biotechnology and diagnostics industry, similar to compensation structures seen at companies like Guardant Health or Exact Sciences, aiming to align executive incentives with shareholder value creation.
• The specific vesting condition tied to a significant stock price increase (10-day VWAP exceeding $40 per share) represents a strong performance hurdle, which is often seen in growth-oriented companies seeking to incentivize substantial long-term value creation, comparable to similar performance-based equity awards at peer companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential benefit from aligned executive incentives, as the CFO is motivated to increase the company's stock price to meet the vesting condition.
• Employees: No direct impact mentioned, but a successful stock performance could indirectly benefit all employees through a stronger company outlook.

Next Steps

• The company's common stock must achieve a 10-day volume-weighted average price exceeding $40 per share for the granted options to vest.

Key Dates

Keywords

Precipio, PRPO, Stock Options, Executive Compensation, Form 4, Insider Transaction, CFO, Equity Incentive Plan, VWAP, Performance-based compensation